Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MYHGeY5kfGmxbjDBd5NigQ>? M3exVlAvPcLizszN NYro[VhlOjRiaB?= MVH3ZZRmeg>? NE\pR5hud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? NHjqbZEzPTF{M{C4Ni=>
Eca109 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\FRXB1OC53L{KuOU82KM7:TR?= M2XodlI1NzR6L{eyJIg> NFv4fG54[XSnch?= NWXSUWtEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NV\pXlA3OjVzMkOwPFI>
Eca109 NEPuVFFHfW6ldHnvckBCe3OjeR?= NW\HO25bOC53wrFOwG0> NFziXmY3NzF{L{K0JIg> NH\qZXF4[XSnch?= MnzobY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= M{XqTlI2OTJ|MEiy
Eca109 MUTGeY5kfGmxbjDBd5NigQ>? M{Tq[FAvPcLizszN M4L6c|I1KGh? M2XCfpdifGW{ M2XJ[YlvcGmkaYTzJINmdGxiaX72ZZNqd25? Moi5NlUyOjNyOEK=
Eca109 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GxOFAvPcLizszN M3L4elI1KGh? NWTXZYc{f2G2ZYK= MljYbY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> NEX1dYUzPTF{M{C4Ni=>
Eca109 M1WwPGZ2dmO2aX;uJGF{e2G7 M1SwOlAvPS9zIN88US=> NWnDR3VTOjRiaB?= NUO0eotqf2G2ZYK= NH61bGJl\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{ MV2yOVEzOzB6Mh?=
SW1116  MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP6enpvOC53L{GvNk82KM7:TR?= MmXGOFghcA>? NYHSOnRnTE2VTx?= M4DIToVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> MnHsNlQ5PzR{OE[=
LOVO M4jQWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[3TlBSOC53L{GvNk82KM7:TR?= MV60PEBp MoLrSG1UVw>? NGnEbY5mdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v NGP3WIgzPDh5NEK4Oi=>
SW1116  M{PpXmZ2dmO2aX;uJGF{e2G7 NHKye|EyOCEQvF2= MYW0PEBp NUHHNIh{TE2VTx?= MkPTbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj M1nKXVI1QDd2Mki2
LOVO NHXlTmVHfW6ldHnvckBCe3OjeR?= M33MTFExKM7:TR?= NX;IUGFvPDhiaB?= NFm1XIZFVVOR MljEbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MUWyOFg4PDJ6Nh?=
SW1116  NYDZPZV4SXCxcITvd4l{KEG|c3H5 M3nISlExKM7:TR?= NGHuWFA1QCCq NHTTU29FVVOR Mln3[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MYiyOFg4PDJ6Nh?=
LOVO M2DNeWFxd3C2b4Ppd{BCe3OjeR?= MmnCNVAh|ryP M{iyVVQ5KGh? M{nGXmROW09? NVvGfHN1\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ NVrvVVcyOjR6N{SyPFY>
RPMI-8226 MWnBdI9xfG:|aYOgRZN{[Xl? Mmf3NU8zKM7:TR?= NEfqR4k1QC95Mj:5OkBp NGLIe41FVVOR M2HRT4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXzqZYV7OjR6M{OxNFg>
OPM-2  MkXvRZBweHSxc3nzJGF{e2G7 M4Pad|EwOiEQvF2= NH;2XIo4Oi97Nj:xNlAhcA>? MXnEUXNQ MmSzbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M2XDWFI1QDN|MUC4
JJN3  MkC2RZBweHSxc3nzJGF{e2G7 MmDsNE42NzFizszN MViyOE81QCCq NFXJeYxFVVOR MVHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mm\wNlQ5OzNzMEi=
NCI-H929  MU\BdI9xfG:|aYOgRZN{[Xl? MUKxM|Ih|ryP MXG3Nk86Pi9zMkCgbC=> MV\EUXNQ MXTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXvZTYd1OjR6M{OxNFg>
RPMI-8226 NXLrPWRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fZdVEwOiEQvF2= MoLHNlQwPDhxN{KgbC=> Mn:xSG1UVw>? MYfh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MoOzNlQ5OzNzMEi=
OPM-2  NWjD[pA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m1ZlEwOiEQvF2= NV7NS2JoOjRxNEivO|IhcA>? M2G3ZmROW09? MkHpZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NYD6SoFxOjR6M{OxNFg>
JJN3  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[yV3V4OC53L{Gg{txO NX3sZ3RzOjRxNEivO|IhcA>? M1;DeWROW09? M3rqOIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 NF\RdngzPDh|M{GwPC=>
NCI-H929  MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLyNU8zKM7:TR?= MWiyOE81QC95MjDo Mk\VSG1UVw>? MYLh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NEfMUlUzPDh|M{GwPC=>
HeLa MWjLbY5ie2ViQYPzZZk> M{fOOmtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> MViyOFc5ODB7OB?=
HeLa NFvUXWJMcW6jc3WgRZN{[Xl? NF;jUVJMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> MV2yOFc5ODB7OB?=
HeLa NXTnPWRPU2mwYYPlJGF{e2G7 NGi4SGpMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy M3fwd|I1PzhyMEm4
HeLa M{fu[2tqdmG|ZTDBd5NigQ>? MX\LbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz NHTr[mozPDd6MEC5PC=>
NB4 NIfaXFhHfW6ldHnvckBCe3OjeR?= M2PuXFIvPS93L{euOU8yOCEQvF2= MXuyOEBp MlvrSG1UVw>? NXu2bolLcW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? MWGyOFQ5PDh5MB?=
CD4+ CD25− T  MWjGeY5kfGmxbjDBd5NigQ>? MV2xM|Uh|ryP M4fpbZJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? NHfNXIYzPDR5NkO2NC=>
BV-173 NX31N3UySXCxcITvd4l{KEG|c3H5 MmXzNE4zPS9yLkWvNE44PS9zIN88US=> NXHmTmlCPDhxN{KvPVYhcA>? NHnx[YPDqFCEUx?= NWTGeoticW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MUOyOFQzOzZzMx?=
ML-1 MWHBdI9xfG:|aYOgRZN{[Xl? NHPlcpIxNjJ3L{CuOU8xNjd3L{Gg{txO M4H3SFQ5Nzd{L{m2JIg> NH7NXpPDqFCEUx?= MkPubY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MYOyOFQzOzZzMx?=
HL-60 NGLmTYhCeG:ydH;zbZMhSXO|YYm= MW[wMlI2NzBwNT:wMlc2NzFizszN MlvROFgwPzJxOU[gbC=> MYlCpHBDWw>? NWjEO45pcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M2jIN|I1PDJ|NkGz
KG-1a NULWR5Z1SXCxcITvd4l{KEG|c3H5 NHO5O2kxNjJ3L{CuOU8xNjd3L{Gg{txO M1\5[|Q5Nzd{L{m2JIg> MnTHxsBRSlN? Mn3tbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NYX1cGM2OjR2MkO2NVM>
BV-173 MUHGeY5kfGmxbjDBd5NigQ>? MoDGNlUxNzVyMH7N M4LYSVQ5KGh? MljBxsBRSlN? MXPpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NEDmZ5IzPDR{M{[xNy=>
CEM MYrGeY5kfGmxbjDBd5NigQ>? NYe3cmxSOjVyL{WwNI5O NUDZS2NMPDhiaB?= MUlCpHBDWw>? MnTnbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NF;hUmwzPDR{M{[xNy=>
HL-60 NYmwSm5KTnWwY4Tpc44hSXO|YYm= NVLuVW03OjVyL{WwNI5O M{LJVVQ5KGh? M1TwbuKhWEKV MnvxbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MYGyOFQzOzZzMx?=
ML-1 M1XHcmZ2dmO2aX;uJGF{e2G7 NUDHcYViOjVyL{WwNI5O NHzvVXM1QCCq Ml3jxsBRSlN? MXzpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MmHwNlQ1OjN4MUO=
DLD-1 MUnGeY5kfGmxbjDBd5NigQ>? MXOyOVAwPTBybl2= Ml;ROFghcA>? NVWx[5NMyqCSQmO= Mon6[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? MnHFNlQ1OjN4MUO=
HCT-116 MV7GeY5kfGmxbjDBd5NigQ>? M2\sRVI2OC93MEDuUS=> NF[3fZg1QCCq NGPs[FTDqFCEUx?= MUjkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NIHGTXMzPDR{M{[xNy=>
U937-A/E-9/14/18  NVvkSJBRSXCxcITvd4l{KEG|c3H5 NWnjZVMzOC5yMT:wMlEwOS9zMDFOwG0> M1fr[FQ5KGh? MXzpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2DpblI1OzByNEW2
HT29 NXXxXoYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLrSJM4OiCq M4LNb2lEPTB;MUSwNOKyOTd7IN88US=> NF\EPZkzPDF5MkC2NS=>
SW48 NWTB[ldRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTxO|IhcA>? NFfxTGpKSzVyPUG1MlLDuTZwMjFOwG0> M4PX[VI1OTd{ME[x
HCT116 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHhVmc4OiCq NEHSd2JKSzVyPUGuO:KyOC52IN88US=> NVXzTGVlOjRzN{KwOlE>
HepG2 MlzhSpVv[3Srb36gRZN{[Xl? M3mwUlAvPS9zIN88US=> NWrTV4JUOjRiaB?= MlH6SG1UVw>? NYq4VXk2fXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NGLHV3kzPDF2Nki3OC=>
LS174T NInGWHZHfW6ldHnvckBCe3OjeR?= M4rQRVAvPS9zIN88US=> MmfrNlQhcA>? Mki2SG1UVw>? NGXyOmZt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> M2jQblI1OTR4OEe0
HepG2 NGXH[FBCeG:ydH;zbZMhSXO|YYm= MVOxM|ExNzFyMDFOwG0> M33vZlch\A>? MUnEUXNQ MnvlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MmXyNlQyPDZ6N{S=
LS174T NH3XeYJCeG:ydH;zbZMhSXO|YYm= MVSxM|ExNzFyMDFOwG0> MoC1O{Bl NXHYfI9KTE2VTx?= NVXwd2tXcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MV6yOFE1Pjh5NB?=
QBC-939 M2rENGFxd3C2b4Ppd{BCe3OjeR?= NVPob5czOS9zMD:xNFAh|ryP MYG3JIQ> Mk\wSG1UVw>? NV;1NlBqcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NGD2VYMzPDF2Nki3OC=>
U251 M4W5U2Fxd3C2b4Ppd{BCe3OjeR?= NX\YcnNpOS9zMD:xNFAh|ryP M3POV|ch\A>? MWjEUXNQ NH:0VopqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWLRdGlROjRzNE[4O|Q>
HL-60 NYHEboF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUG3R2Q1OSEQvF2= M4GzVVQ5KGh? NF7aOJhqdmO{ZXHz[ZMhTzJvcHjhd4Uh[2WubDDmdoFkfGmxbh?= MVmyOFAxODN{NB?=
MDA‑MB‑453 NGnye29HfW6ldHnvckBCe3OjeR?= NUTKbYxPOC5{L{Gg{txO Ml32O|IhcA>? NH2zOGlk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> Ml7nNlM5PDR{Mki=
HCC1569 MkGzSpVv[3Srb36gRZN{[Xl? NIDlPWgxNjJxMTFOwG0> M3LYPVczKGh? MXnjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MYSyN|g1PDJ{OB?=
BT‑474 NVHGTIZNTnWwY4Tpc44hSXO|YYm= NH\rclcxNjJxMTFOwG0> M3TMR|czKGh? NYTMeYw1[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NXjFT25NOjN6NESyNlg>
AGS MojuRZBweHSxc3nzJGF{e2G7 NH;kZW02NzFyL{KwM|UxKM7:TR?= MmjmOFjDqGkEoB?= NXH5b4tYTE2VTx?= MX7pcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NGPZOnEzOzV6Mke4OC=>
A549 NV3YTWVDSXCxcITvd4l{KEG|c3H5 Mkn6OU8yOC9{MD:1NEDPxE1? M3rsbFQ5yqCqwrC= MY\EUXNQ MnTqbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> Ml3aNlM2QDJ5OES=
AGS  M3vweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVG1M|ExNzJyL{WwJO69VQ>? MkH3OFjDqGkEoB?= M1nKcGROW09? NUjl[FVicW6mdXPld{BIOi:PIIDoZZNmKGG{cnXzeOKh NXu4TI85OjN3OEK3PFQ>
Kasumi-1 M1PEUGFxd3C2b4Ppd{BCe3OjeR?= NV31TppTOC53IN88US=> MX:0POKhcMLi NXPqToFy\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MWmyN|Q6OzN2OB?=
OCI-AML3 M2PoWWFxd3C2b4Ppd{BCe3OjeR?= NHnPdYszNjVizszN MkXDOFjDqGkEoB?= NEDSN4Fl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MorMNlM1QTN|NEi=
MV4-11 NGf0PFlCeG:ydH;zbZMhSXO|YYm= NGjmRY4zNjVizszN NVG3bYlqPDkEoHlCpC=> Mmmz[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MVqyN|Q6OzN2OB?=
NK  NEnnZ2dEgXSxdH;4bZR6KEG|c3H5 M3PKR|AvODJvMkCg{txO MlLKOUBl NHTwSXll\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n MUSyN|MzQDB6OB?=
NK  MY\BdI9xfG:|aYOgRZN{[Xl? MonHNE4xOi1{MDFOwG0> MnHGOUBl NH3Mc5ll\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? Mon3NlM{OjhyOEi=
NK  MYTGeY5kfGmxbjDBd5NigQ>? MXWwMlAyNTJyIN88US=> NX[0dYhHPSCm M1fMWYNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> MoT1NlM{OjhyOEi=
MOLT4/DNR MUfGeY5kfGmxbjDBd5NigQ>? NEf5OmU2KM7:TR?= M13ISVQh\A>? M3;yU5Jm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v NEDXcoUzOzB4MEW3NC=>
Jurkat/DOX NFnXS3ZHfW6ldHnvckBCe3OjeR?= M{HUOFUh|ryP M4TyblQh\A>? MnnsdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NVPNUo5xOjNyNkC1O|A>
MOLT4/DNR NH[zeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTDb202KM7:TR?= NIHrfXo1KGR? NIDFVVVz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 M3jl[FI{ODZyNUew
Jurkat/DOX NIDLT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITLRW02KM7:TR?= NWrlSIZmPCCm M3nRW5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= NFzidVAzOzB4MEW3NC=>
ccRCC  M2H1XGFxd3C2b4Ppd{BCe3OjeR?= Ml;vNE4xOS1zMN88US=> NFfiSog4OiCq NYjm[JJCTE2VTx?= MYXoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NGTUfZUzOjh{NkS2Oy=>
TNBC  M3XNUmFxd3C2b4Ppd{BCe3OjeR?= NEfjVpoxNjBzLUGw{txO NEHwbVk4OiCq MnfCSG1UVw>? M4rtVohieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? MXOyNlgzPjR4Nx?=
A498 Mo\rRZBweHSxc3nzJGF{e2G7 MmjTNE4xOS1zMN88US=> M2DuN|czKGh? NYDPOHNsTE2VTx?= NFKyRZdqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M4LPdFIzQDJ4NE[3
KIJ265T NFq4NpRCeG:ydH;zbZMhSXO|YYm= M3H5[VAvODFvMUFOwG0> NVLacmozPzJiaB?= NYnqN4RnTE2VTx?= MU\pcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NHrUO2wzOjh{NkS2Oy=>
MDA-231 NET5b5RCeG:ydH;zbZMhSXO|YYm= NV;CWWo4OC5yMT2xNO69VQ>? NWjw[o5SPzJiaB?= MkHiSG1UVw>? MkLObY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MnzoNlI5OjZ2Nke=
BT-20 NWPQe4J4SXCxcITvd4l{KEG|c3H5 NHjJcpAxNjBzLUGw{txO NELvVXE4OiCq M3exbmROW09? MV\pcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu M1;VclIzQDJ4NE[3
U937 NX;EW29wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHLSHZoPS1{MDFOwG0> MnToNlQwPDhxN{KgbC=> NG\0SVNqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NVnOfIxjOjJ5NkewNlE>
HL60 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOzNYs2NTJyIN88US=> MVWyOE81QC95MjDo M3HxZ4lv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NWj1WZRZOjJ5NkewNlE>
U937 NWTDUVNGSXCxcITvd4l{KEG|c3H5 MoDxNVUh|ryP MUOyOE81QC95MjDo NIq3PGhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFLZOmYzOjd4N{CyNS=>
HL60 NWHEVmFCSXCxcITvd4l{KEG|c3H5 NHW3b3YyPSEQvF2= M3Hwb|I1NzR6L{eyJIg> MnjBbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M4nT[FIzPzZ5MEKx
LS411N  Mn;zRZBweHSxc3nzJGF{e2G7 NHfXZosxNjVizszN NUjNS3pvPzJiaB?= NVfJT3R{cW6lcnXhd4V{KE[jczDtVm5CKGyndnXs NF:1dmgzOjR4MU[5OS=>
MDA-MB-231 M1XPTGFxd3C2b4Ppd{BCe3OjeR?= M3vrR|ExKM7:TR?= MUO0PEBp M1PaepJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX;VdG5{OjF6OEe2PVc>
MCF-7  NU\tS3NmSXCxcITvd4l{KEG|c3H5 M2TwT|ExKM7:TR?= M{[yWVQ5KGh? MYny[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWLQeJVQOjF6OEe2PVc>
A375 NFLCWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLT[VcxNjVizszN M3\Yd|EwPS96IHS= MYXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MWOyNVc6PjZ{Mh?=
SKMEL1 MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOwMlUh|ryP NU\XPFhROS93L{ig[C=> NEj3WpdqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NXjxdWh5OjF5OU[2NlI>
SKMEL3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPJNE42KM7:TR?= MlviNU82NzhiZB?= MlzWbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NX;Yc2lmOjF5OU[2NlI>
SKMEL28 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7HZ29JOC53IN88US=> Mn7jNU82NzhiZB?= MkK1bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NG[ySnYzOTd7Nk[yNi=>
MeWo M3LyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKwMlUh|ryP NFHLdo8yNzVxODDk NW\GZZBScW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MoPQNlE4QTZ4MkK=
B16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7hNE42KM7:TR?= NGP0[HcyNzVxODDk Mni4bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NGf5PYEzOTd7Nk[yNi=>
Ly 1 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXvNlQhcA>? M3nU[mlEPTB;Nz6zJO69VQ>? M17YdlIyPzd{MES5
Ly 7 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jGblI1KGh? NHPmepFKSzVyPUGwMlch|ryP MWOyNVc4OjB2OR?=
Su-DHL6 NWjRPG5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDWNlQhcA>? MnHkTWM2OO,:nkKwJO69VQ>? NWnwc3BzOjF5N{KwOFk>
Ly 10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13aclI1KGh? M3LJVGlEPTExvK6yNEDPxE1? NFm4c2wzOTd5MkC0PS=>
RIVA M1z4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\r[Y0zPCCq MVnJR|Ux97zgMkCg{txO M370[FIyPzd{MES5
Su-DHL2 NXXWNJR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGKxcmYzPCCq MkC0TWM2OO,:nkKwJO69VQ>? MUOyNVc4OjB2OR?=
Ly 1 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq0PEBp M1TZUmlEPTB;MD6zOEDPxE1? MYqyNVc4OjB2OR?=
Ly 7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm3S3BKPDhiaB?= M2H2SGlEPTB;MD6wNlUh|ryP NUHPVJlWOjF5N{KwOFk>
Su-DHL6 M2rrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzZOFghcA>? MmTITWM2OO,:nkKwJO69VQ>? Mmm0NlE4PzJyNEm=
Ly 10 NWPJfZBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVm0PEBp MlW1TWM2OD1zLkig{txO Mo\5NlE4PzJyNEm=
RIVA M4nHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX20PEBp NHfZXI5KSzVy78{eNlAh|ryP NI\Oc2MzOTd5MkC0PS=>
Su-DHL2 NWf4dXY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e0flQ5KGh? M4rFV2lEPTB;MUeuOEDPxE1? MljsNlE4PzJyNEm=
Ly 1 NHX6TFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzyfXQ4OiCq M4TwUGlEPTB;MD6wNUDPxE1? NUn5Um1uOjF5N{KwOFk>
Ly 7 M2q5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL3O|IhcA>? MV\JR|UxRTBwMEG4JO69VQ>? MontNlE4PzJyNEm=
Su-DHL6 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz0em5SPzJiaB?= NYfjT2JbUUN3ME2xMlYh|ryP MV[yNVc4OjB2OR?=
Ly 10 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e3b|czKGh? NW\3SWtGUUN3ME2xMlIh|ryP NVzQTnNLOjF5N{KwOFk>
RIVA NFjtPYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[5PFczKGh? Mk\mTWM2OO,:nkKwJO69VQ>? M37xXlIyPzd{MES5
Su-DHL2 NHT0U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfUO|IhcA>? MWfJR|UxRTFzLkKg{txO NGjLc40zOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID